Status:
COMPLETED
Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome
Lead Sponsor:
University of Aberdeen
Conditions:
Diastolic Heart Failure
Eligibility:
All Genders
16-90 years
Phase:
PHASE2
Brief Summary
Up to half of all patients with clinical features of heart failure are found to have normal heart pumping function. Recently the investigators have shown that a drug called perhexiline markedly improv...
Detailed Description
Up to 50% of patients with symptoms of heart failure have a preserved left ventricular ejection fraction (HFpEF syndrome). Current therapy for systolic heart failure is targeted at inducing vasodilati...
Eligibility Criteria
Inclusion
- HFpEF will be defined as:
- Clinical features consistent with heart failure
- LVEF ≥ 50%, with no evidence of significant valvular disease
- No hypertrophic cardiomyopathy, and no evidence of pericardial constriction
- Peak VO2 \< 80% predicted, with RER\>1 and with a pattern of gas exchange on metabolic exercise testing indicating a cardiac cause for limitation)
- Patients recruited will be in sinus rhythm
Exclusion
- BMI \>35
- Objective evidence of lung disease on formal lung function testing
- Reversible myocardial ischaemia on contrast-enhanced myocardial stress Echocardiography, and no evidence of exercise-induced mitral regurgitation (\>2+)
- Impaired hepatic function; known hypersensitivity to perhexiline
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2014
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00839228
Start Date
March 1 2009
End Date
February 1 2014
Last Update
November 5 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Aberdeen
Aberdeen, United Kingdom, AB25 2ZD